News and Trends 29 Apr 2017 These Bioartists Turn Cell-to-Cell Communication in your Body into Sound Thought Collider and David Young have developed an installation that transforms the faint communication signals between your skin cells into sounds. Artist duo Thought Collider is comprised of Mike Thompson, from the UK, and Susana Cámara Leret, from Spain. Based in Amsterdam and London, they experiment with the living nature of our bodies and microorganisms. Their […] April 29, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Apr 2017 The Tires of the Future will be made with… Dandelions? Continental, famous producer of tires, is creating a research facility in Germany to investigate the use of rubber extracted from dandelions. An eventual switch to the material would mean less environmental impact, and maybe even better tires. The “green pet project” of Continental, a giant automotive manufacturer with almost €40Bn yearly revenues, consists of replacing conventional natural […] April 28, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
Startup Scout 28 Apr 2017 This Dutch Biotech Could Boost Gene Editing of Primary Cells Located in the charming town of Utrecht in the Netherlands, Ntrans Technologies was newly founded in 2015 based on a cutting-edge intracellular delivery technology developed at the Hubrecht Institute of the Royal Netherlands Academy of Sciences. Mission: NTrans is developing the iTOP technology for its use in research and as a therapeutical platform for the delivery of bioactive molecules into […] April 28, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 27 Apr 2017 Heptares Finds New GPCR Target to Treat Pain, Cancer and Inflammation Heptares Therapeutics has published the detailed structure and mechanism of action of a difficult-to-target GPCR protein with great therapeutic prospects. Heptares Therapeutics has published today in Nature new insights into the mechanism of action of antagonists of the protease-activated receptor 2 (PAR2), a molecule involved in metabolism and inflammatory responses. The study is part of […] April 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 27 Apr 2017 Spain: An Emerging Star in the European Biotech Community Take note, Spain is becoming a new hotspot for biotech in Europe. More than €400M of venture capital, counting recent fundraising and anticipated closings, is forecasted to be available this year to fund the creation and growth of start-ups in the life sciences sector. Behind the growing interest among investors are novel opportunities with breakthrough potential […] April 27, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2017 Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy Genfit has announced that closing of enrollment will be delayed up to 6 months. Will this affect its chances to be the first to launch a treatment for NASH? The French biotech Genfit is leading the race to launch the first treatment ever for non-alcoholic steatohepatitis (NASH), a liver disease that affects 30 million people worldwide and has […] April 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2017 New French Biotech Seed Fund Raises €65M in its First Closing Advent France Biotechnology has launched its first seed fund for Life Sciences with the support of Bpifrance and Advent Life Sciences. Advent France Biotechnology, founded in 2015, has exceeded its initial fundraising target at the first closing. Its Seed-Fund I now counts with €64.75M that will be invested predominantly in France. The funds will back entrepreneurs […] April 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2017 French Oncolytic Virus Vaccine for Breast Cancer enters Phase II After positive results in Phase I, Transgene has started Phase II with Pexa-Vec in combination with chemotherapy to treat breast cancer and sarcoma. After years of financial instability, Transgene is stepping up its game in cancer immunotherapies. Last year, its first Phase III trial and a deal with Merck and Pfizer brought the hopes of investors […] April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2017 France Approves Trials for the First Eye Gene Therapy Free of Viral DNA Eyevensys has received regulatory approval in France to start clinical trials using eye gene therapy technology that eliminates the need for viral vectors. The French biotech Eyevensys has been cleared by the French Product Security Regulatory Agency (ANSM) to proceed into the clinic with its EyeCET platform. The company is developing this gene therapy platform […] April 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 3 Apr 2017 Meet the Co-Founder who says DNA is the Next Silicon DNA Script opens the door to a whole new age of manufacturing synthetic DNA. Thomas Ybert, was only 30 when he co-founded the company – here’s his story! Based in Paris, DNA Script produces synthetic DNA using a proprietary template-free enzymatic technology. Most of the manufactured DNA is currently synthesized by chemical means, but this startup […] April 3, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2017 French Synbio Company gets ready to break into Cosmetics After biofuels and carotenoids, Deinove is now moving forward on the cosmetics front. Its engineered microbes can produce a number of interesting chemicals for skin care, and Deinove plans to bring them to market until the end of 2018. Deinove is a key synbio biotech in France and has found a wide range of applications for […] March 31, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 29 Mar 2017 French Gene Therapy Biotech Gets Ready for Phase II/III Lysogene has crunched the numbers on its observational study for Sanfillipo A – now the company can move into the final phase for its Sanfilippo A therapy. Lysogene is a French biotech specializing in gene therapy of rare CNS diseases. Its lead asset is a gene therapy for the treatment of the rare genetic disorder […] March 29, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email